References
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
- Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193:1572-80
- Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567-85
- Krhut J, Gartner M, Petzel M, et al. Persistence with first line anticholinergic medication in treatment-naive overactive bladder patients. Scand J Urol 2014;48:79-83
- Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189:2186-93
- Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64:249-56
- Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22
- Osborn DJ, Kaufman MR, Mock S, et al. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn 2015;34:675-8
- Botox [PI]. Dublin, Ireland: Allergan plc, 2017. Available at: http://www.allergan.com/assets/pdf/botox_pi.pdf. Last accessed April 14th, 2017
- Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics 2014;8:227-41
- Flynn MK, Amundsen CL, Perevich M, et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009;181:2608-15
- Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177:2231-6
- Milhouse O, Johnson M, Gross L, Siegel S. Real-world retention rates after intravesical onabotulinumtoxinA for idiopathic overactive bladder. J Urol 2015;193:E574
- Lewthwaite B, Girouard L. Urinary drainage following continence surgery: development of Canadian best practice guidelines. Urol Nurs 2006;26:33-9
- Buchko BL, Robinson LE, Bell TD. Translating an evidence-based algorithm to decrease early post-operative urinary retention after urogynecologic surgery. Urol Nurs 2013;33:24-8, 32
- Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175(3 Pt 1):999-1004, discussion 1004
- MacDiarmid SA, Ellsworth PI, Ginsberg DA, et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology 2011;77:24-9
- Geller EJ. Prevention and management of postoperative urinary retention after urogynecologic surgery. Int J Womens Health 2014;6:829-38
- Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxina injection for refractory idiopathic detrusor overactivity. J Urol 2013;189:1804-10
- Jiang YH, Liao CH, Tang DL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS One 2014;9:e105989
- Macdiarmid SA. Maximizing the treatment of overactive bladder in the elderly. Rev Urol 2008;10:6-13
- Everaert K, Gruenenfelder J, Schulte-Baukloh H, et al. Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: a pooled analysis of two randomized controlled trials. Int J Urol 2015;22:1131-7